Results 121 to 130 of about 17,784 (227)

The ‘Health Collapse Spiral’: A 35‐Month Longitudinal Case Study of Physiological Reserve Depletion in a Centenarian Following COVID‐19

open access: yesClinical Case Reports, Volume 14, Issue 6, June 2026.
ABSTRACT This 35‐month case report documents irreversible physiological reserve depletion in a centenarian multimorbid man after COVID‐19. Prior to infection, he maintained precarious homeostasis for 17 years despite severe frailty (CFS 7), with stable CKD stage 3a (eGFR 58.3 mL/min/1.73 m2) and albumin 36.2 g/L.
Shan Xu   +5 more
wiley   +1 more source

Drugs Targeting Cough Receptors: New Therapeutic Options in Refractory or Unexplained Chronic Cough

open access: yes
International audienceRefractory chronic cough is a disabling disease with very limited therapeutic options. A better understanding of cough pathophysiology has led to the development of emerging drugs targeting cough receptors.
Grassin-Delyle, Stanislas   +2 more
core   +1 more source

Randomised clinical trial: gabapentin vs baclofen in the treatment of suspected refractory gastro‐oesophageal reflux‐induced chronic cough

open access: yes, 2019
Background: Neuromodulators are considered potential therapeutic options for refractory gastro-oesophageal reflux-induced chronic cough. Aim: To compare the efficacy of gabapentin and baclofen in patients with suspected refractory gastro-oesophageal ...
Li Yu   +21 more
core   +1 more source

Spinal Cord Involvement in Neurosarcoidosis: A Case of Longitudinally Extensive Transverse Myelitis at Disease Onset

open access: yesClinical Case Reports, Volume 14, Issue 6, June 2026.
ABSTRACT Acute‐onset neurological deficits in otherwise healthy individuals warrant a broad differential diagnosis. Neurosarcoidosis presenting as longitudinally extensive transverse myelitis is rare, mimicking demyelinating, infectious, or neoplastic disorders. Early recognition, histopathological confirmation, and timely immunosuppressive therapy are
Areeb Tiwana   +2 more
wiley   +1 more source

Exploring the concept of disease control in chronic cough

open access: yesERJ Open Research
Background Disease control in chronic diseases is an overarching concept that reflects the degree to which the goals of therapy are met. However, to date, there is no consensus on the definition of disease control in chronic cough.
Jin Young Park   +21 more
doaj   +1 more source

Cough reflex sensitivity improves with speech language pathology management of refractory chronic cough

open access: yes
Rationale: Speech language pathology is an effective management intervention for chronic cough that persists despite medical treatment. The mechanism behind the improvement has not been determined but may include active cough suppression, reduced cough ...
Anne Vertigan (21132566)   +3 more
core  

Programmed Cell Death in Chronic Rhinosinusitis

open access: yesClinical and Translational Allergy, Volume 16, Issue 6, June 2026.
ABSTRACT Chronic rhinosinusitis (CRS) is a prevalent upper respiratory condition characterized by a multifaceted etiology involving various cellular and molecular processes. In recent years, researchers have increasingly recognized the significance of different forms of programmed cell death (PCD), such as apoptosis and pyroptosis, in the pathological ...
Xingchen Liu   +5 more
wiley   +1 more source

Refractory Chronic Cough at the Crossroads

open access: yesArchivos de Bronconeumología (English Edition), 2020
openaire   +2 more sources

KCNJ4 variants disrupt inward‐rectifier potassium channel function and cause refractory epilepsy

open access: yesEpilepsia, Volume 67, Issue 6, Page 3199-3210, June 2026.
Abstract Objective Epilepsy is a common neurological disorder with a strong genetic basis, most frequently arising from ion channel dysfunction. Although multiple inwardly rectifying potassium (Kir) channels have been implicated in epileptogenesis, the contribution of KCNJ4, which encodes the Kir2.3 channel, has not previously been established in human
Hu Pan   +20 more
wiley   +1 more source

Phase 3 PERSPECTIVE study: Ibrutinib with rituximab for initial treatment of patients with follicular lymphoma

open access: yesHemaSphere, Volume 10, Issue 6, June 2026.
Abstract We report primary analysis results from the Phase 3 PERSPECTIVE study comparing ibrutinib + rituximab versus placebo + rituximab in patients with previously untreated follicular lymphoma requiring treatment per Groupe d'Etude des Lymphomes Folliculaires criteria who were ineligible for chemoimmunotherapy due to age and/or comorbidities.
David Belada   +17 more
wiley   +1 more source

Home - About - Disclaimer - Privacy